CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Dianthus Therapeutics, Inc. /DE/ (DNTH) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Dianthus Therapeutics, Inc. /DE/ (DNTH)

Pharmaceutical Preparations · market cap $5.2B · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Dianthus Therapeutics (DNTH) is a 78-employee biotech with a ~$4.44B market cap (~55.9M shares at ~$79.33). Its lead asset, claseprubart, is listed in Phase 3 for Multifocal Motor Neuropathy (MMN), and the pipeline also lists DNTH103 in Phase 3 for generalized Myasthenia Gravis. Our calendar shows an estimated earnings date of 2026-11-04 and an estimated claseprubart catalyst on 2026-12-15. The data has gaps and internal inconsistencies, flagged below.
The catalyst path
  • 2026-12-15 (est.)Phase 2 · Claseprubartimp 7/10
  • 2026-12-31 (est.)Earningsimp 5/10
Pipeline
AssetPhaseIndication
DNTH103Phase 3Myasthenia Gravis, Generalized
ClaseprubartPhase 3Multifocal Motor Neuropathy
Price & technical context
3-month
-21.0%
6-month
+3.1%
12-month
+144.8%
52-wk range
$35.50–$115.96
vs 50-day MA
-0.7%
vs 200-day MA
+2.9%
Realized vol
59.3%
Max drawdown
-50.3%

Daily closes through 2026-11-10. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for DNTH (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.